Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure

@article{Catalina2003HepaticAS,
  title={Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure},
  author={Mar{\'i}a Vega Catalina and Jos{\'e} Barrio and F. Galeas Anaya and Magdalena Salcedo and Diego Rinc{\'o}n and Gerardo Clemente and Rafael Ba{\~n}ares},
  journal={Liver International},
  year={2003},
  volume={23}
}
Abstract Hyperdynamic circulation and portal hypertension characterize acute on chronic liver failure (AoCLF), partially because of circulating mediators. Molecular Absorbents Recirculating System (MARS) may remove some of these substances. The objective of this study was to evaluate the effect of MARS on portal pressure, systemic haemodynamic and endogenous vasoactive systems. MARS treatment was performed in four patients with AoCLF (mean age 36.2 ± 3.1 years; Child–Pugh C 11 ± 1.8 points… 
Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis.
TLDR
The results suggest that MARS may be a useful adjunct in management of portal hypertension, particularly in patients with severe AH with associated organ failure.
Hemodynamic Studies in Acute-on-Chronic Liver Failure
TLDR
The portal pressure in patients with ACLF is higher than that in the compensated cirrhotics, and in the subgroup with large varices, it becomes similar to that of decompensated cirRhotics.
Acute-on-chronic liver failure: the heart and systemic hemodynamics
TLDR
Patients treated with molecular adsorbent recirculating system (MARS) had improved serum levels of inflammatory mediators such as tumor necrosis factor alpha and interleukin-6, but this was not associated with improved survival.
Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure
TLDR
The MARS device, and not the Prometheus device, significantly attenuates the hyperdynamic circulation in acute-on-chronic liver failure, presumably by a difference in removal rate of certain vasoactive substances.
Effect of Prometheus liver assist system on systemic hemodynamics in patients with cirrhosis: a randomized controlled study.
TLDR
Extra-corporal liver support with Prometheus is proven to be safe in patients with endstage liver disease but does not exert the beneficial effects on arterial pressure as seen in the MARS group.
Effects of Intraperitoneal Albumin on Systemic and Cerebral Hemodynamics in a Swine Model of Acute Liver Failure
TLDR
This study provides the first evidence that intraperitoneal albumin may be able to attenuate systemic, pulmonary, and cerebral hemodynamic disturbances associated with acute liver failure.
Artificial liver support systems in the management of complications of cirrhosis.
TLDR
Better understanding of the pathophysiology of ACLF, further development of the current systems, and their evaluation in appropriately controlled clinical studies are necessary to translate their application to improvement in outcome of patients with ACLF.
Dialysis reduces portal pressure in patients with chronic hepatitis C.
TLDR
In patients with chronic hepatitis C, concomitant TJLB and hepatic venous pressure gradient measurement identify those who have early fibrosis and portal hypertension, which may reduce portal pressure in these patients.
Acute-on-chronic liver failure: extracorporeal liver assist devices
TLDR
Liver support systems are safe and well tolerated when used in management of patients with ACLF and should continue in controlled clinical trials to explore their role in bridging patients to liver transplantation or recovery in well defined patient groups.
Adjuvant Therapeutic Plasma Exchange in Liver Failure: Assessments of Clinical and Laboratory Parameters
TLDR
The data suggest that TPE is safe and tolerable in such individuals with acute and chronic liver failure, however, overall survival remains poor despite TPE.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 22 REFERENCES
Hemodynamic changes during a single treatment with the molecular adsorbents recirculating system in patients with acute‐on‐chronic liver failure
TLDR
In conclusion, MARS treatment proved safe in critically ill patients with no attributing side effects and systemic hemodynamic variables were determined before and during treatment.
Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis.
TLDR
Paracentesis-induced circulatory dysfunction is predominantly caused by an accentuation of the arteriolar vasodilation already present in untreated cirrhotic patients with ascites, and the homeostatic activation of endogenous vasoactive systems may account for the increased intrahepatic vascular resistance associated with this condition.
The effect of nitric oxide synthase inhibition on portal pressure and azygos blood flow in patients with cirrhosis.
TLDR
A significant systemic effect of nitric oxide synthase inhibition in patients with cirrhosis is demonstrated but no effect upon the portal or portosystemic collateral circulations at this dose.
Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure.
TLDR
It is concluded that the molecular adsorbent recirculating system can contribute to the treatment of critically ill patients with liver failure and different underlying diseases.
Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure
TLDR
Applying MARS treatments to patients with acute exacerbation of chronic liver disease can detoxify blood, improve cerebral circulation, and reduce brain edema, as reflected by the reduction in intracranial pressure and jugular bulb oxygen saturation values in the authors' patients.
Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis
TLDR
Results indicate that in patients with compensated cirrhosis, portal hypertension and hyperdynamic circulation inhibition of nitric oxide synthase corrects the altered systemic hemodynamics and improves renal function and sodium excretion.
Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators.
TLDR
It is concluded that part of the increased resistance to flow through the portal vascular bed of the cirrhotic rat liver in vitro is due to an increase in intrinsic vascular tone, possibly mediated via myofibroblasts, and can be reversed by pharmacological agents.
The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enough
TLDR
The purpose of this review is to summarize the chemical reactions in which NO participates and the effects mediated by those reactions, give a short overview of the regulation of NOS, and outline the available data and current concepts regarding the involvement of NO in the hemodynamic abnormalities associated with liver cirrhosis.
Verapamil favorably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver.
TLDR
The microvascular distortions of liver cirrhosis in the rat are partially reversible by vasodilators like verapamil, which is associated with a significant improvement in oxygen consumption and antipyrine clearance.
Tumor necrosis factor and interleukin‐6 in spontaneous bacterial peritonitis in cirrhosis: Relationship with the development of renal impairment and mortality
TLDR
The inflammatory response to the infection may be an important mechanism of renal impairment and the associated mortality in spontaneous bacterial peritonitis.
...
1
2
3
...